

=> => file caplus
FILE 'CAPLUS' ENTERED AT 16:36:58 ON 09 FEB 2005

FILE COVERS 1907 - 9 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 8 Feb 2005 (20050208/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 78 SEA FILE=REGISTRY SSS FUL L1
L3 135 SEA FILE=CAPLUS L2 AND SODIUM
L4 7 SEA FILE=CAPLUS L3 AND CRYSTAL?

=> d l4 1-7 fbib abs hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1016027 CAPLUS
DN 142:23317
TI Preparation of 1,3,4-benzotriazepin-2-ones as CCK2 (gastrin) receptor antagonists for the treatment of gastrointestinal disorders
IN Abdel-Magid, Ahmed F.; Cohen, Judith H.

10/786,556

PA Johnson & Johnson, USA
SO PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004101533	A1	20041125	WO 2004-US12914	20040427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2003-469659P	P 20030512
US 2005026911	A1	20050203	US 2004-833232	20040427
			US 2003-469659P	P 20030512

GI



I



II

AB 1,3,4-Benzotriazepinones or 1,3,4-benzotriazepin-2-one N-oxides I [R1, R5 = H, alkyl, alkoxy, alkylthio, HO2C, OHC, alkylcarbonyl, alkoxycarbonyl, O2N, F3C, etc.; R2, R4 = H, (un)substituted alkyl with up to three substitutions of carbon atoms for N, O, or S; R3 = (CR11R12)mX(CR13R14)pR9; R9 = H, (un)substituted alkyl, Ph, naphthyl, pyridinyl, benzimidazolyl, indazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, etc.; R11, R12, R13, R14 = H, alkyl; W = N or N(:O); m = 0-4; p = 0-2] such as II are prepared as gastrin (CCK2) receptor antagonists for the treatment of

gastrointestinal disorders. E.g., condensation of cyclohexyl (2-aminophenyl) ketone and Et hydrazinoacetate hydrochloride, cyclocondensation with triphosgene, N-alkylation with 1-bromo-3,3-dimethyl-2-butanone, hydrolysis with **sodium** hydroxide and acidification, and EDC/HOBt-mediated amidation with Me 3-aminobenzoate yields II. Data for the inhibition of gastrin receptors in rat stomach are given for most of the example compds.; data for competition expts. with human gastrin expts. are given for some of the example compds. E.g., II inhibits gastrin receptors in rat stomach with a pKb value of 8.55 ± 0.32. **Crystal** structures of the **sodium**, potassium, choline, and tert-butylamine salts of one of the invention compds. are determined

IT **117976-89-3**, Rabeprazole **177795-59-4**, (S)-Rabeprazole **177795-60-7**, (R)-Rabeprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of 1,3,4-benzotriazepin-2-ones as CCK2 (gastrin) receptor antagonists for the treatment of gastrointestinal disorders)

RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 177795-59-4 CAPLUS
CN 1H-Benzimidazole, 2-[(S)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 177795-60-7 CAPLUS
CN 1H-Benzimidazole, 2-[(R)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:716152 CAPLUS
DN 141:212799
TI Preparation of the polymorphic **crystalline** form Z of rabeprazole **sodium**
IN Venkatraman, Sundaram; Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Bhaskar, Bolugoddu Vijaya; Reddy, Pingili Ramchandra; Rajiv, Ireddy; Babu, Thirunava Karasu Ananda
PA Dr. Reddy's Laboratories Ltd., India
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1452533	A1	20040901	EP 2004-4420	20040226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			IN 2003-MA156 A	20030228
US 2004180935	A1	20040916	US 2004-786556	20040225
			IN 2003-MA156 A	20030228
CA 2459012	AA	20040828	CA 2004-2459012	20040226
			IN 2003-MA156 A	20030228

AB The crystalline form Z of rabeprazole **sodium** is prepared and characterized by its X-ray diffraction pattern, and pharmaceutical dosage forms containing the crystalline form Z are prepared
IT **117976-90-6P**, Rabeprazole **sodium**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of the polymorphic crystalline form Z of rabeprazole **sodium**)
RN 117976-90-6 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



IT **117976-89-3P**, Rabeprazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of the polymorphic crystalline form Z of rabeprazole **sodium**)
RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:525965 CAPLUS
DN 141:76745
TI Method for the preparation of coated drugs and dietary supplements that include substances with a concentration gradient in the coating
IN Petereit, Hans-Ulrich; Meier, Christian; Roth, Erna
PA Roehm GmbH & Co. Kg, Germany
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10260919	A1	20040701	DE 2002-10260919	20021220
WO 2004058225	A1	20040715	WO 2003-EP11540	20031018

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 2002-10260919 A 20021220

AB The invention concerns the preparation of coatings for drugs and dietary supplements in a way that the concentration of the coating ingredients decrease or increase from the inner side of the coating to the outer side; the concentration gradient is achieved by spraying the components in form of solns. or dispersions from two or more nozzles; the components mix with each other during spraying and after evaporation a film is formed around the core. Cores are drug **crystals**, tablets, granules, pellets etc. Acid-sensitive substances can be coated with (meth)acrylate copolymers containing anionic groups in a way that the layers close to the cores contain neutralized anionic groups or a base; the outer layers contain increasing amts. of non-neutralized polymer or decreasing amts. of base. Similarly, base- or dye-sensitive substances can be coated by avoiding the critical component next to the core and increasing its concentration to the outer layer. Thus a first spraying fluid contained (g): Eudragit L30 D-55 300; 1N **sodium** hydroxide 250; water 1050. The second spraying fluid included (g): Eudragit L30 D-55 300; 1N **sodium** hydroxide 250; pigment suspension 750; water 300. The pigment suspension was composed of (g): talc 100; titanium dioxide 50; color pigment 50; polyethylene glycol 6000 50; trisodium acetate citrate 5.5 hydrate 62; antifoaming agent 1; water 687.

IT **117976-89-3**, Rabeprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acid-sensitive, coating of; method for preparation of coated drugs and dietary supplements that include substances with a concentration gradient in coating)

RN 117976-89-3 CAPLUS

CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:796694 CAPLUS

DN 139:307762

TI Preparation of polymorphic **crystalline** forms of rabeprazole **sodium**

IN Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Bolugoddu, Vijaya Bhaskar; Pingili, Ramchandra Reddy; Ganta, Madhusudhan Reddy

PA Reddy's Laboratories Limited, India; Cord, Janet I.

SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082858	A1	20031009	WO 2003-US9307	20030325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			IN 2002-MA207	A 20020326
EP 1487820	A1	20041222	EP 2003-721471	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			IN 2002-MA207	A 20020326
			WO 2003-US9307	W 20030325

AB Methods of making polymorphic forms of rabeprazole **sodium** [i.e., 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole **sodium**] are presented in which: (a) one dissolves 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole in a C1-4 alkanol (e.g., methanol) containing **sodium** hydroxide,distilling the solvent from the reaction solution; and (b) adding chlorinated C1-3 hydrocarbon (e.g., methylene chloride) solvent(s)to the residual mass obtained in step (a).

IT **117976-89-3**, Rabeprazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of polymorphic crystalline forms of rabeprazole **sodium**)

RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



IT **117976-90-6P**, Rabeprazole **sodium**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polymorphic crystalline forms of rabeprazole **sodium**)
RN 117976-90-6 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:610242 CAPLUS
DN 139:154933
TI Transmucosal delivery of proton pump inhibitors
IN Widder, Ken; Hall, Warren; Olmstead, Kay
PA Santarus, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063840	A2	20030807	WO 2003-US2659	20030127
	WO 2003063840	A3	20030904		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-351909P P 20020125
US 2002-374761P P 20020422
US 2004006111 A1 20040108 US 2003-353143 20030127
US 2002-351909P P 20020125
US 2002-374761P P 20020422
EP 1469839 A2 20041027 EP 2003-705972 20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2002-351909P P 20020125
US 2002-374761P P 20020422
WO 2003-US2659 W 20030127

AB The present invention relates to pharmaceutical compns. and methods for transmucosal delivery of proton pump inhibitors. In one embodiment, the pharmaceutical composition of the present invention comprises a core which comprises an antacid, and an outer layer surrounding the core. The outer layer contains a therapeutically effective amount of a proton pump inhibitor. In another embodiment, the pharmaceutical composition of the present invention comprises an outer layer which comprising a unidirectional film, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. In yet another embodiment, the pharmaceutical composition of the present invention is a unidirectional tablet for delivery of a proton pump inhibitor across the oral mucosa. In this embodiment, the pharmaceutical composition contains an outer layer which contains a pharmaceutically acceptable water impermeable layer, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. A tablet composition contained in the outer layer; Klucel EXP 10, dicalcium phosphate 10, MgCO3-90S 20, FD&C Lake Red Number 0.1, and Compitol-888 1 mg/tablet; the inner layer comprised omeprazole 20, MgCO3-90S 20, Klucel EXP 10, and Mg stearate 0.6 mg/tablet.

IT **117976-89-3**, Rabeprazole **117976-90-6**, Pariprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal delivery of proton pump inhibitors)

RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 117976-90-6 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:338762 CAPLUS
DN 134:362292
TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
IN Farr, Spencer
PA Phase-1 Molecular Toxicology, USA
SO PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

IT **117976-89-3**, Rabeprazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(methods of determining individual hypersensitivity to a pharmaceutical agent
from gene expression profile)
RN 117976-89-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:644880 CAPLUS
DN 126:46780
TI Preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810)
AU Nochi, Shigeharu; Kawai, Takatoshi; Kawakami, Yoshiyuki; Asakawa, Naoki; Ueda, Norihiro; Hayashi, Kenji; Souda, Shigeru
CS Tsukuba Res. Labs., Eisai Co., Ltd., Ibaraki, 300-26, Japan
SO Chemical & Pharmaceutical Bulletin (1996), 44(10), 1853-1857
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 126:46780
AB The optical isomers of **sodium** 2[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-2H-benzimidazole (E3810), a proton pump inhibitor, were separated by HPLC and their absolute configurations were determined by
x-ray **crystallog.** anal.
IT **184713-30-2P**
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(**crystallog.**; preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810))
RN 184713-30-2 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1-[(phenylmethoxy)methyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



IT **117976-90-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); RCT (Reactant); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent)
(preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810))
RN 117976-90-6 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)



IT **184713-27-7P 184713-28-8P 184713-29-9P**
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810))
RN 184713-27-7 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 184713-28-8 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-

pyridinyl]methyl]sulfinyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 184713-29-9 CAPLUS
CN 1H-Benzimidazole, 1-(methoxymethyl)-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



IT **177795-59-4P 177795-60-7P**
RL: PNU (Preparation, unclassified); PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810))
RN 177795-59-4 CAPLUS
CN 1H-Benzimidazole, 2-[(S)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 177795-60-7 CAPLUS
CN 1H-Benzimidazole, 2-[(R)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **184713-31-3P 184713-32-4P 184713-33-5P**
184713-34-6P 184713-35-7P
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810))

RN 184713-31-3 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1-[(phenylmethoxy)methyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 184713-32-4 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 184713-33-5 CAPLUS
CN 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 184713-34-6 CAPLUS
CN 1H-Benzimidazole, 1-(methoxymethyl)-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 184713-35-7 CAPLUS
CN 1H-Benzimidazole, 1-(methoxymethyl)-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT **171440-18-9P 171440-19-0P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configurations of optical isomers of **sodium** 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810))
RN 171440-18-9 CAPLUS
CN 1H-Benzimidazole, 2-[(R)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● Na

RN 171440-19-0 CAPLUS
CN 1H-Benzimidazole, 2-[(S)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

=>